Jan 13 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Monday it plans to buy Scorpion Therapeutics' experimental cancer therapy for up to $2.5 billion in cash to expand its pipeline of ...

Eli Lilly stock down 19% in May, on track for worst month since 2009. But June historically brings better fortune, with 67% ...

Eli Lilly has agreed to acquire Scorpion Therapeutics’ breast cancer treatment program for up to $2.5 billion in cash. The drugmaker said Monday it is acquiring Scorpion and its STX-478 program ...

Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a cancer therapy being developed by Scorpion Therapeutics in a third major transaction announced on the first day of the JP Morgan ...

Shares of Eli Lilly (NYSE: LLY ... the guidance reduction stems from an up-front payment it made to acquire Scorpion Therapeutics' STX-478 program to treat breast cancer. This is a one-time ...

Eli Lilly’s (NYSE: LLY) first-quarter performance was mixed, with revenue meeting expectations but earnings falling short. The company reported adjusted earnings of $3.34 per share versus the ...

Eli Lilly on Thursday reported first-quarter ... related to its acquisition of a certain oral cancer drug from Scorpion Therapeutics. The company maintained its fiscal 2025 sales guidance of ...

Ultimately, is Eli Lilly still a buy despite these detrimental ... charge equal to $1.72 per share due to its acquisition of Scorpion Therapeutics. This caused Lilly to reduce its full-year ...